Addendum

Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14

Report documents

Indication:

Patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more

Result of dossier assessment:

Now added benefit not proven for any of the three subindications

2018-08-16 A G-BA decision was published.

Project no.: A18-47
Commission: Commission awarded on 09.07.2018 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.